Preventive effect of a heparinoid-containing product on the application site reaction of the rotigotine transdermal patch in Parkinson’s disease: A pilot randomized clinical trial (the SkinHeRo study)
Introduction: The rotigotine transdermal patch (RTP) is a dopamine agonist used to treat Parkinson’s disease (PD) but is sometimes discontinued because of application site reactions (ASRs). We aimed to investigate the effect of a heparinoid-containing product (HCP) for preventing ASRs due to the RTP...
Main Authors: | Jinsoo Koh, Maiko Takahashi, Mayumi Sakata, Masaaki Yasui, Shoko Yorozu, Hidefumi Ito |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Clinical Parkinsonism & Related Disorders |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590112521000177 |
Similar Items
-
A Study for Expanding Application Sites for Rotigotine Transdermal Patch
by: Hitoshi Kujirai, et al.
Published: (2020-01-01) -
Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis.
by: Chang-Qing Zhou, et al.
Published: (2013-01-01) -
Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
by: Kim Han-Joon, et al.
Published: (2011-08-01) -
The efficacy of the dopamine agonist Rotigotine in the treatment of Parkinson's disease
by: Marina Romanovna Nodel
Published: (2013-11-01) -
Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch
by: Trenkwalder Claudia, et al.
Published: (2010-09-01)